Edition:
India

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
24 Nov 2017
Change (% chg)

$0.02 (+2.79%)
Prev Close
$0.57
Open
$0.57
Day's High
$0.60
Day's Low
$0.57
Volume
28,797
Avg. Vol
103,534
52-wk High
$3.10
52-wk Low
$0.55

Select another date:

Mon, Nov 13 2017

BRIEF-Trovagene Inc updates on clinical trial for PCM-075

* Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075

BRIEF-TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12

* ‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​ Source text: (http://bit.ly/2hgteK4) Further company coverage:

BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing

* Trovagene Inc files for offering of up to $17.5 million - SEC filing Source text: (http://bit.ly/2zOQs1P) Further company coverage:

BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga

* Trovagene Inc - ‍announced positive data from preclinical research demonstrating synergy of PCM-075 in combination with abiraterone (Zytiga)​

BRIEF-Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075

* Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML)

BRIEF-Trovagene files for offering of upto sale 4.64 mln shares of common stock by the selling stockholders‍​

* Trovagene Inc files for offering of up to sale 4.64 million shares of common stock by the selling stockholders‍​ - SEC Filing Source text: (http://bit.ly/2fELxf1) Further company coverage:

BRIEF-Trovagene appoints Athena Countouriotis to its board of directors

* Trovagene strengthens board of directors with appointment of oncology development veteran Dr. Athena Countouriotis Source text for Eikon: Further company coverage:

BRIEF-Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor

* Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy

BRIEF-Trovagene Q2 loss per share $0.26

* Trovagene announces second quarter 2017 company highlights and financial results

BRIEF-Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

* Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

Select another date: